DE102004059674B4 - Transdermal delivery system for scopolamine - Google Patents
Transdermal delivery system for scopolamine Download PDFInfo
- Publication number
- DE102004059674B4 DE102004059674B4 DE102004059674A DE102004059674A DE102004059674B4 DE 102004059674 B4 DE102004059674 B4 DE 102004059674B4 DE 102004059674 A DE102004059674 A DE 102004059674A DE 102004059674 A DE102004059674 A DE 102004059674A DE 102004059674 B4 DE102004059674 B4 DE 102004059674B4
- Authority
- DE
- Germany
- Prior art keywords
- delivery system
- transdermal delivery
- matrix
- scopolamine
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Abstract
Transdermales Abgabesystem umfassend:
– eine Trägerfolie;
– eine Matrix aus einem Styrol-Butadien-Copolymer-Haftkleber, die den Wirkstoff Scopolamin mit einer Abgabe von 500 μg bis 2 mg über mindestens bis zu 72 h und einen Penetrationsförderer enthält, der unter den folgenden Verbindungen ausgewählt ist:
Ethanol, Aloe Vera, umgeesterten, polyethoxylierten nichtionogenen Triglyceriden, polyethoxyliertem Ricinusöl, Polyethylenglycol und dessen Derivaten, Glycerol, Stearin, Tocopherol, Macrogol, Oleyloleat, Polyoxyethylen-Polyoxypropylen-Blockcopolymeren, Polyoxyethylensorbitanestern, Cholsäureestern, Capryl/Caprin-Triglyceriden, Natriumstearat, Myristylmyristinsäureestern, Linolensäure, Polyethylenglycolnachtprimelglyceriden, Acrylsäure-Polymerisaten, Olivenöl, Natriumlaurylethersulfat, umgeesterten, polyethoxylierten Caprylcaprinsäureglyceriden, Octyldodecyllactat, Ethoxydiglycolbehenat, ethoxylierten Sorbitanfettsäureestern und Ölsäure;
wobei keine die Geschwindigkeit kontrollierende Membran enthalten ist; und
– eine Schutzlage.Transdermal delivery system comprising:
A carrier film;
A matrix of a styrene-butadiene copolymer pressure-sensitive adhesive containing the active substance scopolamine with a delivery of 500 μg to 2 mg for at least up to 72 hours and a penetration promoter selected from the following compounds:
Ethanol, aloe vera, transesterified, polyethoxylated nonionic triglycerides, polyethoxylated castor oil, polyethylene glycol and its derivatives, glycerol, stearin, tocopherol, macrogol, oleyl oleate, polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene sorbitan esters, cholic acid esters, caprylic / capric triglycerides, sodium stearate, myristyl myristic acid esters, linolenic acid , Polyethylene glycol pentahelglycerides, acrylic acid polymers, olive oil, sodium lauryl ether sulfate, transesterified polyethoxylated caprylcaprylic acid glycerides, octyldodecyl lactate, ethoxydiglycol behenate, ethoxylated sorbitan fatty acid esters and oleic acid;
no speed controlling membrane is included; and
- a protective layer.
Description
Bereits
auf dem Markt befindliche Scopolamin-TDS, wie z. B. Transderm Scop®,
weisen relativ komplizierte Zusammensetzungen auf.
Transderm
Scop® wie
in
Die
Die
Druckschriften
Die Erfindung betrifft ein transdermales Abgabesystem, umfassend Scopolamin als Wirkstoff und eine Matrix, umfassend einen Styrol-Butadien-Copolymer Haftkleber.The The invention relates to a transdermal delivery system comprising scopolamine as an active ingredient and a matrix comprising a styrene-butadiene copolymer Pressure sensitive adhesive.
Die Matrix des transdermalen Abgabesystems kann einen Styrol-Butadien-Styrol-Blockcopolymer Haftkleber umfassen.The Matrix of the transdermal delivery system may be a styrene-butadiene-styrene block copolymer Include pressure-sensitive adhesive.
Des Weiteren kann das transdermale Abgabesystem eine Trägerfolie, die Matrix und eine Schutzdecklage umfassen und keine die Geschwindigkeit kontrollierende Membran.Of Furthermore, the transdermal delivery system may include a carrier foil, the matrix and a protective cover layer and not the speed controlling membrane.
Des Weiteren kann das transdermale Abgabesystem eine Trägerfolie, die Matrix und eine Schutdecklage und eine die Geschwindigkeit kontrollierende Membran umfassen.Of Furthermore, the transdermal delivery system may include a carrier foil, the matrix and a protective layer and a speed controlling Membrane include.
Des Weiteren kann die Matrix des transdermalen Abgabesystems einen Permeationsförderer umfassen, vorzugsweise einen Permeationsförderer ausgewählt aus der Gruppe, bestehend aus
- – Ethanol,
- – Aloe Vera,
- – Labrafil,
- – Cremophor,
- – Polyethylenglycol und dessen Derivate,
- – Löslichmacher Gamma,
- – Glycerol,
- – Stearin,
- – Tocopherol (Vitamin E),
- – Macrogol,
- – Oleyloleat,
- – Pluronic,
- – Polyoxyethylensorbitanester,
- – Cholsäureester,
- – Benzalkoniumchlorid,
- – Capryl/Caprin-Triglyceride,
- – Dodecanol,
- – Natriumstearat,
- – Myristylmyristinsäureester,
- – Linolensäure,
- – Mineralöl,
- – Crovol,
- – Carbopol,
- – Controx,
- – Olivenöl,
- – Texapon,
- – Cetiol,
- – Labrasol,
- – Octyldodecyllactat,
- – Softcutol und
- – Tween
- Ethanol,
- - aloe vera,
- - Labrafil,
- - Cremophor,
- Polyethylene glycol and its derivatives,
- Solubilizer gamma,
- - glycerol,
- - stearin,
- - tocopherol (vitamin E),
- - Macrogol,
- Oleyl oleate,
- - Pluronic,
- - polyoxyethylene sorbitan ester,
- - cholic acid ester,
- - benzalkonium chloride,
- Caprylic / capric triglycerides,
- - dodecanol,
- Sodium stearate,
- Myristyl myristic acid ester,
- - linolenic acid,
- - mineral oil,
- - Crovol,
- - Carbopol,
- - Controx,
- - olive oil,
- - Texapon,
- - Cetiol,
- - Labrasol,
- Octyldodecyl lactate,
- - Softcutol and
- - Tween
Des Weiteren kann, was das transdermale Abgabesystem betrifft, der Scopolamingehalt 5 bis 15 und insbesondere etwa 10 Gew.-% sein, basierend auf der Matrix.Furthermore, as far as the transdermal delivery system is concerned, the scopolamine content may be 5 to 15 and especially about 10% by weight on the matrix.
Des Weiteren kann, was das transdermale Abgabesystem betrifft, der Scopolamingehalt einer Abgabe von 500 μg bis 2 mg und insbesondere etwa 1 mg über mindestens bis zu 72 h entsprechen.Of Further, as far as the transdermal delivery system is concerned, the level of scopolamine may be a delivery of 500 μg to 2 mg and especially about 1 mg for at least up to 72 h correspond.
Des Weiteren kann, was das transdermale Abgabesystem betrifft, der Scopolamingehalt einer Abgabe entsprechen, die einem Blutspiegel von etwa 87 pg/ml über mindestens bis zu 72 h entspricht.Of Further, as far as the transdermal delivery system is concerned, the level of scopolamine may be corresponding to a blood level of about 87 pg / ml over at least up to 72 h.
Des Weiteren kann das transdermale Abgabesystem ein kreisförmiges, ovales, rechteckiges oder quadratisches Matrixpflaster sein.Of Further, the transdermal delivery system may be a circular, oval, rectangular or square matrix plaster.
Des Weiteren kann das transdermale Abgabesystem eine Größe von 1,0 bis 3,0 und insbesondere 1,5 bis 2,5 cm2 haben.Furthermore, the transdermal delivery system may have a size of 1.0 to 3.0 and in particular 1.5 to 2.5 cm 2 .
Des Weiteren kann, was das transdermale Abgabesystem betrifft, die Matrix ein Flächengewicht von 40 bis 140, vorzugsweise 80 bis 100, und insbesondere etwa 90 g/m2 haben.Furthermore, as far as the transdermal delivery system is concerned, the matrix may have a basis weight of 40 to 140, preferably 80 to 100, and most preferably about 90 g / m 2 .
Das erfindungsgemäße transdermale Abgabesystem kann für die Behandlung von Bewegungskrankheit bereitgestellt werden.The Transdermal according to the invention Dispensing system can for the treatment of motion sickness will be provided.
Schließlich kann das erfindungsgemäße transdermale Abgabesystem für die Behandlung von postoperativer Übelkeit bereitgestellt werden.Finally, can the transdermal invention Delivery system for the treatment of postoperative nausea will be provided.
Überraschend
wurde festgestellt, dass ein linearer Fluss mit den benötigten Spiegeln über 72 Stunden
mit a) einem weitaus geringeren Matrixgewicht und b) sogar ohne
die Verwendung einer die Geschwindigkeit kontrollierenden Membran
erreicht werden konnte. Der Fluss von Scopolamin aus dem hierin
beschriebenen Scopolamin-TDS wurde festgestellt, ähnlich zu
dem aus Transderm Scop® zu sein (Verweis auf
Ein transdermales Abgabesystem (TDS) für Scopolamin wurde für die Behandlung von Bewegungskrankheit entwickelt. Das Abgabeziel für Scopolamin ist annähernd 1 mg über 72 Stunden, um Blutspiegel von annähernd 87 pg/ml zu ergeben.One transdermal delivery system (TDS) for scopolamine was used for the treatment developed from motion sickness. The delivery target for scopolamine is approximate 1 mg over 72 hours to give blood levels of approximately 87 pg / ml.
Das
Scopolamin-TDS besteht aus einem kreisförmigen Matrixpflaster mit einer
Fläche
von 1,5 bis 2,5 cm2 und einem Flächengewicht
von etwa 90 g/m2, die Aktivmatrix enthält einen
Styrol-Butadien-Styrol-Copolymer Haftkleber (PSA) (DT-6173) mit 10%
Scopolamin. Verweis auf
- 1. Fachinformation, Scopoderm TTS®, Novartis Consumer Health GmbH, 2003.
- 2. J. E. Shaw, J. Urquhart & S.
K. Chandrasekaran: Verband zur transdermalen Verabreichung von Scopolamin,
um Übelkeit
zu verhindern,
US-Patent 4,031,894 - 3. J. W. Dohner & S.
A. Bura: Verbessertes Verfahren zur Verhinderung der Kristallbildung
in einer Dispersion einer Flüssigkeit
in einer Matrix,
EP-Patent 0 863 751 - 4. J. W. Dohner, S. A. Bura & R.
E. Ford: Verfahren zur Verhinderung der Kristallbildung in einer
Dispersion einer Flüssigkeit
in einer Matrix,
US-Patent 6,238,700 - 5. J. W. Dohner, S. A. Bura & R.
E. Ford: Verfahren zur Verhinderung der Kristallbildung in einer
Dispersion einer Flüssigkeit
in einer Matrix,
US-Patent 6,569,448 - 6. R. M. Gale & D.
J. Enscore: Transdermale Abgabe aus einem wässrigen Reservoir,
US-Patent 4,904,475
- 1. prescribing information, Scopoderm TTS ®, Novartis Consumer Health GmbH., 2003
- 2. JE Shaw, J. Urquhart & SK Chandrasekaran: Association for transdermal administration of scopolamine to prevent nausea
U.S. Patent 4,031,894 - 3. JW Dohner & SA Bura: Improved method of preventing crystal formation in a dispersion of a liquid in a matrix,
European Patent 0 863 751 - 4. JW Dohner, SA Bura & RE Ford: Method of preventing crystal formation in a dispersion of a liquid in a matrix,
U.S. Patent 6,238,700 - 5. JW Dohner, SA Bura & RE Ford: Method of preventing crystal formation in a dispersion of a liquid in a matrix,
U.S. Patent 6,569,448 - 6. RM Gale & DJ Enscore: Transdermal delivery from an aqueous reservoir,
U.S. Patent 4,904,475
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004059674A DE102004059674B4 (en) | 2004-12-10 | 2004-12-10 | Transdermal delivery system for scopolamine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004059674A DE102004059674B4 (en) | 2004-12-10 | 2004-12-10 | Transdermal delivery system for scopolamine |
Publications (2)
Publication Number | Publication Date |
---|---|
DE102004059674A1 DE102004059674A1 (en) | 2006-06-14 |
DE102004059674B4 true DE102004059674B4 (en) | 2010-05-06 |
Family
ID=36500210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102004059674A Active DE102004059674B4 (en) | 2004-12-10 | 2004-12-10 | Transdermal delivery system for scopolamine |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE102004059674B4 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018118507A1 (en) * | 2018-07-31 | 2020-02-06 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the delivery of scopolamine without a membrane |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2667861A4 (en) * | 2011-01-26 | 2014-07-16 | Csi Gmbh | Extended-release beta agonist/anticholinergic transdermal patches and methods for using the same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904475A (en) * | 1985-05-03 | 1990-02-27 | Alza Corporation | Transdermal delivery of drugs from an aqueous reservoir |
EP0356382A2 (en) * | 1988-08-02 | 1990-02-28 | Ciba-Geigy Ag | Multilayer plaster |
DE3910543A1 (en) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | TRANSDERMAL THERAPEUTIC SYSTEM WITH INCREASED ACTIVE FLUID AND METHOD FOR THE PRODUCTION THEREOF |
DE19825499A1 (en) * | 1998-06-08 | 1999-12-09 | Beiersdorf Ag | Patches containing active ingredient |
US20010006628A1 (en) * | 1997-06-26 | 2001-07-05 | Govil Sharad K. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
US6465004B1 (en) * | 1999-06-05 | 2002-10-15 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
DE69622780T2 (en) * | 1995-04-28 | 2003-04-03 | Lead Chem Co Ltd | Transdermal therapeutic system with controlled drug release |
WO2004098472A1 (en) * | 2002-08-30 | 2004-11-18 | Watson Pharmaceuticals, Inc. | Transdermal delivery systems and methods |
-
2004
- 2004-12-10 DE DE102004059674A patent/DE102004059674B4/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904475A (en) * | 1985-05-03 | 1990-02-27 | Alza Corporation | Transdermal delivery of drugs from an aqueous reservoir |
EP0356382A2 (en) * | 1988-08-02 | 1990-02-28 | Ciba-Geigy Ag | Multilayer plaster |
DE3910543A1 (en) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | TRANSDERMAL THERAPEUTIC SYSTEM WITH INCREASED ACTIVE FLUID AND METHOD FOR THE PRODUCTION THEREOF |
DE69622780T2 (en) * | 1995-04-28 | 2003-04-03 | Lead Chem Co Ltd | Transdermal therapeutic system with controlled drug release |
US20010006628A1 (en) * | 1997-06-26 | 2001-07-05 | Govil Sharad K. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
DE19825499A1 (en) * | 1998-06-08 | 1999-12-09 | Beiersdorf Ag | Patches containing active ingredient |
US6465004B1 (en) * | 1999-06-05 | 2002-10-15 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
WO2004098472A1 (en) * | 2002-08-30 | 2004-11-18 | Watson Pharmaceuticals, Inc. | Transdermal delivery systems and methods |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018118507A1 (en) * | 2018-07-31 | 2020-02-06 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the delivery of scopolamine without a membrane |
WO2020025695A1 (en) | 2018-07-31 | 2020-02-06 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for dispensing scopolamine without a membrane |
Also Published As
Publication number | Publication date |
---|---|
DE102004059674A1 (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0680325B1 (en) | Transdermal therapeutic system with galanthamine as active ingredient | |
EP1490052B1 (en) | Device for the transdermal administration of a rotigotine base | |
EP0813865B1 (en) | Drug patch | |
EP2515886B1 (en) | Transdermal therapeutic system for administering rivastigmine or derivatives thereof | |
DE60314298T2 (en) | THERAPEUTIC PLASTER WITH CAPSAICIN-CONTAINING POLYSILOXAN MATRIX | |
EP2468274B1 (en) | Transdermal therapeutic system for application of an agent | |
DE10141651B4 (en) | Transdermal Therapeutic System (TTS) with the active ingredient Fentanyl and process for its preparation | |
DE112014002664T5 (en) | Transdermal delivery system | |
EP2295046B1 (en) | Transdermal therapeutic system for application of fentanyl or an analogue material thereof | |
DE102010024105A1 (en) | Transdermal administration of memantine | |
EP2111857A1 (en) | Transdermal therapeutic system for application of fentanyl or an analogue material thereof | |
EP2173330B1 (en) | Reservoir system comprising a closed membrane | |
DE60311449T2 (en) | TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO MATERIAL MATRIX LAYERS PROVIDING DIFFERENT AFFINITY TO THE INGREDIENT SUBSTANCE | |
DE102007021549A1 (en) | Transdermal therapeutic system containing at least two opioids | |
EP1152751B1 (en) | Desoxypeganine transdermal therapeutic system | |
DE60309329T2 (en) | IMPROVED TRANSDERMAL DELIVERY SYSTEM | |
DE102004059674B4 (en) | Transdermal delivery system for scopolamine | |
EP0742716B1 (en) | Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide | |
EP2366388A1 (en) | Non-occlusive transdermal therapeutic system for administering buprenorphine | |
DE60108870T2 (en) | Transdermal delivery system for the treatment of urinary tract disorders | |
EP0659079B1 (en) | Transdermal therapeutic system with pentylene tetrazol as active substance | |
EP3829550B1 (en) | Transdermal therapeutic system for dispensing scopolamine without a membrane | |
EP1216700A1 (en) | Transdermal systems comprising (R)-(-)-methylphenyloxazolidinone derivatives, inhibitors of type IV phosphodiesterase | |
EP3651744B1 (en) | Fampridine tts | |
EP0668074A1 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8127 | New person/name/address of the applicant |
Owner name: ACINO AG, 83714 MIESBACH, DE |
|
8181 | Inventor (new situation) |
Inventor name: MCLEOD, SARAH, 81675 MUENCHEN, DE Inventor name: MEYER, ELISABETH, 83714 MIESBACH, DE |
|
8364 | No opposition during term of opposition | ||
R081 | Change of applicant/patentee |
Owner name: LUYE PHARMA AG, DE Free format text: FORMER OWNER: ACINO AG, 83714 MIESBACH, DE |
|
R082 | Change of representative |
Representative=s name: BEETZ & PARTNER MBB PATENTANWAELTE, DE Representative=s name: BEETZ & PARTNER MBB PATENT- UND RECHTSANWAELTE, DE |